• Subscribe
  • Log In
  • Home
  • Daily Diary
  • Asset Class
    • U.S. Equity
    • Fixed Income
    • Global Equity
    • Commodities
    • Currencies
  • Sector
    • Basic Materials
    • Consumer Discretionary
    • Consumer Staples
    • Energy
    • Financial Services
    • Healthcare
    • Industrials
    • Real Estate
    • Technology
    • Telecom Services
    • Transportation
    • Utilities
  • Latest
    • Articles
    • Video
    • Columnist Conversations
    • Best Ideas
    • Stock of the Day
  • Street Notes
  • Authors
    • Bruce Kamich
    • Doug Kass
    • Jim "Rev Shark" DePorre
    • Helene Meisler
    • Jonathan Heller
    • - See All -
  • Options
  • RMPIA
  • Switch Product
    • Action Alerts PLUS
    • Quant Ratings
    • Real Money
    • Real Money Pro
    • Retirement
    • Stocks Under $10
    • TheStreet
    • Top Stocks
    • TheStreet Smarts
  1. Home
  2. / Investing
  3. / Stocks

Psychedelics May Find Legit Place in Pharma as Pandemic Takes Toll

As crisis turns into one of mental health as well as physical health, some firms are experimenting with use of LSD and 'magic mushroom' compounds.
By DEBRA BORCHARDT
Apr 02, 2020 | 05:00 PM EDT
Stocks quotes in this article: MMEDF, SHRMF

The coronavirus pandemic has tested the psychological state of many. Social distancing and staying isolated, as well as general fear of the virus, has wreaked havoc on even those with the strongest mindsets. People who have struggled with mental illness prior to the Covid-19 crisis are finding themselves in an even tougher position.

One promising treatment for depression -- even when traditional drugs don't work -- may turn out to be psychedelics, including possibly, forms of the controversial hallucinogen, LSD.

And the demand for such remedies is likely sizable. According to the World Health Organization, almost 350 million people worldwide were affected by depression in 2016. In the U.S., the percentage of people above the age of 12 using antidepressants rose to 12.7% from 2011 to 2014, the Centers for Disease Control and Prevention reported.

This has created a big market for medications. The antidepressant drug market was valued at $13.69 billion in 2018 and is expected to reach $15.88 billion by 2025, according to MedGadget. Antidepressants were the most commonly prescribed drugs in 2013 and from over 16 million long-term users, around 70% are female, according to the CDC. 

Can MindMed Mend Minds?

In June 2019, the neuro-pharmaceutical company Mind Medicine Inc. ( MMEDF)  or MindMed, as it is known, finalized its acquisition of its "18-MC" drug development program, which is an anti-addictive molecule that was previously funded by the National Institute on Drug Abuse, for $6.8 million. MindMed acquired the project from a company called Savant HWP Inc., whose leadership team of researchers and drug developers joined MindMed.

The company also just signed a multi-year deal for an exclusive collaboration with Professor Dr. Matthias Liechti, a psychedelics pharmacology and clinical research expert at University Hospital Basel in Switzerland. Dr. Liechti is considered an expert, too, in LSD, technically known as lysergic acid diethylamide. Through the deal, MindMed will get the exclusive worldwide rights to data, compounds, and patent rights associated with Liechti's lab research on LSD and other psychedelic compounds, including data from preclinical studies and eight completed or ongoing LSD clinical trials. 

MindMed said it is particularly interested in the data and outcome of an ongoing placebo-controlled, phase 2 trial of high dose LSD for the treatment of anxiety. The company said it is considering the creation of a drug development program using hallucinogenic doses of LSD for the treatment of anxiety disorders.

The Potential 'Magic' of Champignon

Champignon Brands Inc. (SHRMF)  -- which focuses on psilocybin and other compounds found in some types of mushrooms -- is also pursuing the development and commercialization of treatments for conditions like depression and post-traumatic stress disorder, as well as substance and alcohol abuse disorders. Late last week, the company announced that it was acquiring Tassili Life Sciences Corp. in an all-stock deal that was valued at roughly $5.2 million.

The acquisition expands Champignon's preclinical trial pipeline and its aggregation of broad intellectual property associated with the development of novel psychedelics that will target psychological diseases. 

Tassili has been working with physicians at the University of Miami who are working to develop effective psilocybin-based therapeutics for the treatment of mild traumatic brain injuries and post-traumatic stress disorder. Its focus is a proprietary combination of psilocybin and CBD.

In addition to the Tassili acquisition, Champignon also said in March that it was buying Novo Formulations. That firm is working on ketamine treatments in a deal valued at approximately $2.1 million. Champignon said it plans to leverage Novo Formulations' existing product development infrastructure and licensed affiliates to pursue psilocybin- and MDMA-based drugs to develop and then commercialize treatments for depression and PTSD.

While business and development are in the early stages for these companies, the demand for their services could amplify as a result of the pandemic. It is a trying time for everyone and if people need help for mental health and these companies are there to provide that help without stigma, then they could benefit along with their customers.

Get an email alert each time I write an article for Real Money. Click the "+Follow" next to my byline to this article.

At the time of publication, Borchardt had no positions in any securities mentioned.

TAGS: Investing | Stocks | Healthcare | Cannabis

More from Stocks

How to Trade MongoDB After Its Huge Upside Move

Bruce Kamich
Jun 5, 2023 1:45 PM EDT

Let's check out the charts and indicators for clues.

This Value Portfolio of Lovable Losers Is Down But Not Out

Jonathan Heller
Jun 5, 2023 1:10 PM EDT

With about six months to go, anything can happen for the 2023 Tax Loss Selling Recovery Portfolio.

Friday's Cheer Turns to Monday Drear

James "Rev Shark" DePorre
Jun 5, 2023 11:35 AM EDT

Even the bulls will likely agree that this market needs better participation and breadth.

As Palo Alto Networks Joins the S&P 500, Here's How to Play the Stock

Stephen Guilfoyle
Jun 5, 2023 11:24 AM EDT

This 'best-in-class' cybersecurity name was already hot, before the news.

I'm Placing Bets on a Couple of Giants to Lose Ground in the Coming Months

Bret Jensen
Jun 5, 2023 10:10 AM EDT

This pair of household names easily could pull back based on the economic challenges ahead.

Real Money's message boards are strictly for the open exchange of investment ideas among registered users. Any discussions or subjects off that topic or that do not promote this goal will be removed at the discretion of the site's moderators. Abusive, insensitive or threatening comments will not be tolerated and will be deleted. Thank you for your cooperation. If you have questions, please contact us here.

Email

CANCEL
SUBMIT

Email sent

Thank you, your email to has been sent successfully.

DONE

Oops!

We're sorry. There was a problem trying to send your email to .
Please contact customer support to let us know.

DONE

Please Join or Log In to Email Our Authors.

Email Real Money's Wall Street Pros for further analysis and insight

Already a Subscriber? Login

Columnist Conversation

  • 01:51 PM EDT JAMES "REV SHARK" DEPORRE

    This Weekend on Real Money

    Adjusting Your Trading Approach to Shifting Market...
  • 06:54 PM EDT CHRIS VERSACE

    AAP Podcast: A Tongue -- and a Market -- Twister: 'Get a Debt Deal Done'

    Listen in as the Action Alerts PLUS Podcast tackle...
  • 12:07 PM EDT STEPHEN GUILFOYLE

    Selling Some of This Surging AI-Related Stock

    This isn't the only name in the Stocks Under $10 p...
  • See More

COLUMNIST TWEETS

  • A Twitter List by realmoney
About Privacy Terms of Use

© 1996-2023 TheStreet, Inc., 225 Liberty Street, 27th Floor, New York, NY 10281

Need Help? Contact Customer Service

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data & Company fundamental data provided by FactSet. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by FactSet Digital Solutions Group.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

FactSet calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.

Compare Brokers

Please Join or Log In to manage and receive alerts.

Follow Real Money's Wall Street Pros to receive real-time investing alerts

Already a Subscriber? Login